Human Autoantibodies Against MOG Isoforms: α3 Antibodies Suggest Relapsing Disease Course in Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease.

Authors

Young Nam Kwon, Miguel Leal Rato, Jun-Soon Kim, Kyung Seok Park, Hyung-Soo Lee, Seol-Hee Baek, Byung-Jo Kim, Yeon Hak Chung, Ju-Hong Min, Sooyoung Kim, Eunhee Sohn, Seong-Il Oh, Sang Beom Kim, Seung Woo Kim, Ha Young Shin, Ki Hoon Kim, Ho Jin Kim, Boram Kim, Jung-Joon Sung, Silvia Messina, Mark R Woodhall, Halwan Bayuangga, Maria Isabel Leite, Ruth Geraldes, Jacqueline Palace, Patrick J Waters, Sung-Min Kim

Published in

Neurology(R) neuroimmunology & neuroinflammation. Volume 13. Issue 6. Pages e200660. Epub Sep 23, 2026.

Abstract

A proportion of patients with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) experience relapses, but biomarkers predicting which patients are likely to relapse are not yet widely available. The MOGα1 isoform is the most commonly used in diagnostic MOG antibody assays, while the clinical relevance of antibodies against other MOG isoforms remains unclear.
This study used a stepwise approach using international multicenter serum samples collected prospectively. First, diagnostic accuracy of the MOGα1 and β1 isoforms was compared using 748 consecutive sera from Korean patients suspected of having demyelinating disease of the CNS. Next, the predictive values of antibodies against each of 7 MOG isoforms for relapses were assessed on sera from Korean patients with MOGAD (derivation cohort). Finally, the association between MOG isoform antibody with relapses was validated in 2 independent cohorts: a Korean validation cohort (n = 49) and a UK validation cohort (n = 56).
Both MOGα1 antibody and MOGβ1 antibody assays had comparable diagnostic accuracy. Among patients with MOGAD, the presence of MOGα3 antibody was associated with a higher risk of relapse, with a hazard ratio of 4.3 in the derivation cohort (log-rank p < 0.001). This finding was also confirmed in an independent smaller Korean validation cohort (log-rank p = 0.009) and in a subgroup of UK validation cohort (log-rank p = 0.048).
The presence of MOGα3-IgG in patients with MOGAD may be associated with an increased risk of relapse, indicating that early preventive treatment strategies may be appropriate in these individuals. MOGβ1-IgG demonstrated diagnostic accuracy similar to MOGα1-IgG.
This study provides Class II evidence that MOGα1 antibody and MOGβ1 antibody assays have comparable diagnostic accuracy for MOGAD.

PMID:
42777168
Bibliographic data and abstract were imported from PubMed on 24 Sep 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.